- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
DNDN
4 Stocks to Watch on Dendreon Earnings
Here's a look at how to trade Dendreon on Monday's earnings report, as well as similar smaller companies that tend to move when DNDN moves.
Groupon Deals a Dud — Wednesday’s IP Market Recap
A poor first earnings report is taking an after-hours toll on GRPN shares.
Sweet Day for Shipping — Monday’s IP Market Recap
A tiny rise in the Baltic Dry Index spurs big stock gains for several shipping companies.
Overreacting to a Prostate Cancer Drug?
Medivation shares are soaring on positive test results. But investors may be getting ahead of reality here.
Solar Stocks Flare Up — Wednesday’s IP Market Recap
Two pieces of positive news send JinkoSolar, First Solar and other solar stocks skyward Wednesday after months of battering throughout the sector.
Netflix Soars, Apple Peaks — Monday’s IP Market Recap
The start of a new trading week saw a pair of big-name tech stocks charge at the onset, but only one finished the day on…
First Week of 2012 Is a Hit! — Friday’s IP Market Recap
Markets finish the first week of 2011 in the black, with financial stocks, automakers and the Iowa caucus dominating headlines.
Bold Day for Bank of America — Thursday’s IP Market Recap
Bank of America shares clear $6 for the first time since November, and other U.S. banking giants make gains. Automakers, Dendreon also charge ahead.
Dendreon Jumps 40% on Provenge Sales
Dendreon saw its stock jump Thursday as sales of its cancer drug beat the expectations of both analysts and the company itself.
Boeing Rewrites Its Own Record — Thursday’s IP Market Recap
Boeing (BA) signed a $21.7B deal with Indonesia's Lion Air on Thursday, breaking a company mark it set earlier this week. Also, J.M. Smucker (SJM) disappointed.
Medivation Shares Shoot Up on Prostate Cancer Treatment News
Medivation (MDVN) gains almost 140% Thursday on encouraging results for its prostate cancer treatment, and Dendreon (DNDN) is further battered.
Pharma, Fashion Fallout — Thursday’s IP Market Recap
Dendreon (DNDN), Abercrombie & Fitch (ANF) watched their stocks plummet Thursday after each doled out bad news.
Why Dendreon Is Aiming Prostate Drug Pitches to Consumers
Dendreon (DNDN) appears to be pulling out all the stops in an effort to restore at least some of the luster to its prostate cancer treatment Provenge.
